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Andrea Filippini2, Maria Letizia Bacchi Reggiani3 and Roberto Cevenini1Abstract
Background: We evaluated LGV prevalence and predictors in a high risk population attending a STI Outpatients
Clinic in the North of Italy.
Methods: A total of 108 patients (99 MSM and 9 women), with a history of unsafe anal sexual intercourses, were
enrolled. Anorectal swabs and urine samples were tested for Chlamydia trachomatis (CT) DNA detection by Versant
CT/GC DNA 1.0 Assay (Siemens Healthcare Diagnostics Terrytown, USA). RFLP analysis was used for CT molecular typing.
Results: L2 CT genotype was identified in 13/108 (12%) rectal swabs. All LGV cases were from MSM, declaring
high-risk sexual behaviour and complaining anorectal symptoms. Patients first attending the STI Outpatient Clinic
received a significant earlier LGV diagnosis than those first seeking care from general practitioners or gastroenterologists
(P = 0.0046).
LGV prevalence and characteristics found in our population are in agreement with international reports. Statistical
analysis showed that LGV positive patients were older (P = 0.0008) and presented more STIs (P = 0.0023) than LGV
negative ones, in particular due to syphilis (P < 0.001), HIV (P < 0.001) and HBV (P = 0.001).
Multivariate logistic regression analysis revealed that HIV and syphilis infections are strong risk factors for LGV presence
(respectively, P = 0.001 and P = 0.010).
Conclusions: Even if our results do not provide sufficient evidence to recommend routine screening of anorectal
swabs in high-risk population, they strongly suggest to perform CT NAAT tests and genotyping on rectal specimens in
presence of ulcerative proctitis in HIV and/or syphilis-positive MSM. In this context, CT DNA detection by Versant CT/GC
DNA 1.0 Assay, followed by RFLP analysis for molecular typing demonstrated to be an excellent diagnostic algorithm
for LGV identification.
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Lymphogranuloma venereum (LGV) is a systemic sexually
transmitted infection caused by Chlamydia trachomatis
(CT) serovars L1- L3 [1].
In 2003, a new outbreak of LGV proctitis was described
in the Netherlands, mainly in men who have sex with men
(MSM) [2], leading to an increase awareness for this
disease throughout Europe.* Correspondence: antonella.marangoni@unibo.it
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unless otherwise stated.The first Italian LGV case was observed in Milan in 2006
and only few cases of LGV proctitis have been described
in Italy [3] so far.
In this study we assess LGV prevalence and predictors
in a high-risk population attending a STI Outpatients
Clinic of a University Hospital in the North of Italy.Methods
Study population
From January 2012 to April 2013, all the patients attending
the STI Outpatients Clinic of St. Orsola University Hospital
of Bologna and reporting unsafe anal sexual intercoursesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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anorectal swab, a pharyngeal swab (if reporting oral sex
intercourses) and an urine sample were collected from
each patient for DNA detection of CT and Neisseria
gonorrhoeae (GC).
Microbiological investigations for the main STDs (HIV,
HCV, HBV and syphilis) and a serological screening for
anti-Chlamydia antibodies by immunoenzimatic assays
(Chlamydia IgG and Chlamydia IgA, Virion/Serion GmbH,
Wurzbug, Germany) were performed in all patients.
Diagnosis of genital warts was made by visual inspection.
Furthermore, personal data and information about urogeni-
tal and rectal disorders, sexual behaviour, number of sexual
partners in the last 6 months and history of previous STIs
were recorded from each patient. Three months after anti-
biotic treatment for LGV, patients were re-evaluated.
A written consent was obtained by all the patients and
the study protocol was reviewed by the Ethics committee
of St. Orsola Hospital.
Diagnosis of CT infections and genotyping
Urine specimens, anorectal and pharyngeal swabs were
processed by Versant CT/GC DNA 1.0 Assay (Siemens
Healthcare Diagnostics, Terrytown, USA), a Real-Time
PCR test simultaneously detecting the presence of CT
and/or GC DNA [4]. In case of a CT positive result, mo-
lecular genotyping, based on omp1 gene semi-nested PCR,
followed by RFLP analysis was performed as previously
described [5-7]. GC reactive results were confirmed by
in-house PCR assay targeting porA pseudogene [8].
Statistical analysis
Analyses of the differences between the groups were
performed with χ2 test. Univariate and multiple logistic
regression analyses were performed to evaluate the in-
fluence of the different variables on the outcomes. A P
value <0.05 was considered significant. Statistical tests
were performed using SPSS 13.0 for Windows computer
software (SPSS, Chicago, Illinois).
Results
Patients characteristics
During the study period, a total of 108 patients met our
admission criteria. In particular, 99 MSM (median age:
34.9; range 18–64 years) and 9 heterosexual women
(median age: 35.8; range 19–52 years). Three of the women
and 29 of the MSM complained about various rectal
symptoms.
Diagnosis of CT infections and genotyping
Nineteen rectal swabs resulted positive only for CT and
10 only for GC, whereas 4 were simultaneously scored
positive for CT and GC. Thanks to molecular genotyping,
in 10 cases we found non-LGV serovars CT (6 E, 3D, 1 J),while in 13 cases L2 serovar was identified, coming to the
final diagnosis of LGV proctitis. The total prevalence of
LGV infection was 12% (13/108).
Four urine samples were positive for non-LGV sero-
vars CT, whereas 12 pharyngeal swabs and three urine
specimens were positive for GC. No urine samples nor
pharyngeal swabs were found positive for LGV-serovars
CT. Finally, it is noteworthy to underline that in the high
risk population of this study 38.3% of MSM (38/99) and
37.5% of the women (3/8) had at least one specimen
scored CT or GC positive.
Detailed results are shown in Figure 1.
Clinical findings, risk factors and outcome of LGV cases
Based on rectal swab findings, patients with positive LGV
results were defined as LGV-positive, while all the others
(negative, non-LGV CT or GC cases) as LGV-negative.
All LGV cases were detected in MSM reporting unsafe
receptive anal intercourses in the last 6 months.
In Table 1 statistical differences between LGV positive
and LGV negative groups and logistic regression analysis
to determine risk factors for LGV presence are presented
in Table 2.
All patients suffering from LGV proctitis were symp-
tomatic, complaining about anal pain (13/13), anal dis-
charge (11/13), change in bowel habit (7/13), tenesmus
(9/13) and inguinal adenopathy (5/13). In contrast, pa-
tients with non-LGV CT or GC proctitis were asymptom-
atic or complained about slight symptoms. In particular,
only 30% CT and 40% GC positive patients were symp-
tomatic respectively, in contrast to 100% LGV positive
patients (P < 0.001).
When considering the mean age of LGV positive pa-
tients, we noticed a significant difference between LGV
and non-LGV group (43 years vs. 34 years; P = 0.0008),
as well as comparing LGV cases with non LGV-CT
positive patients (43 years vs. 36 years; P = 0.04).
All LGV positive patients showed altered anti-Chlamydia
IgG values, significantly higher than LGV-negative subjects
(P < 0.001). Moreover, it is interesting to add that patients
infected by non-LGV CT genotypes showed similar results
to CT-negative patients (P = 0.102). Anti-Chlamydia IgA
values were negative or only slight increased with no sig-
nificant differences between studied groups.
All LGV positive patients but one suffered from other
STIs; in particular, 9 were HIV-positive. Six of them were
under HAART-therapy with a well control of the infection
(viral load <1000 copies/ml; CD4 > 500 cells/ml).
When evaluating the distribution of other STIs in
our population, we noticed that LGV positive patients
presented more coinfections than LGV negative subjects
(P = 0.001).
Finally, considering LGV cases, patients first attending
the STI Outpatients Clinic (4/13) received an earlier
Figure 1 CT and GC testing results. Flowchart of testing of 108 high risk subjects for CT and GC by Versant CT/GC DNA 1.0 Assay. Results
obtained by commercial NAAT were confirmed by omp1 and porA in-house PCR assays.
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general practitioners or gastroenterologists. In particular,
in the former group, time taken for LGV diagnosis was
2 weeks (range: 10–18 days), in contrast with the median
of 8 weeks (4–92 weeks) of the latter group (P =0.0046).
First diagnostic hypothesis included inflammatory bowel
diseases (IBD), enteritis and other STIs with rectal
localization such as syphilis or gonorrhoea.
LGV positive patients were treated with doxycycline
100 mg twice a day for 3 weeks. They completely recovered
after antibiotic therapy, regardless of their HIV status,
HIV viral load or CD4 cell count.Table 1 Statistical analysis of the subjects by their LGV status
LGV negative
N = 95
Reported symptoms % (n) 20% (19)
MSM % (n) 91.6% (87)
Mean age (±SD), (range) 34 years (±9.5)
Mean anti-Chlamydia IgG AU/ml, (range)£ 11.8 (4–38)
Presence of coinfections† % (n) 47.3% (45)
HIV % (n) 10.5% (10)
Syphilis % (n) 16.8% (16)
Gonorrhoea* % (n) 17.8% (17)
Non-L serovar CT* % (n) 13.7% (13)
HBV % (n) 3.2% (3)
HCV % (n) 1.1% (1)
HPV warts % (n) 10.5% (10)
† A patient was considered coinfected when at least one of the following infection
*A patient was considered gonorrhoea or non-L CT positive when at least one of th
resulted positive.
£ Normal values: IgG <15 Arbitrary Units/ml.Three months after treatment, rectal swabs and urine
samples were negative both for CT and GC nucleic acids
in all patients but one. This patient had a positive result
for GC and a non-LGV serovar CT in his rectal swab,
with recurrence of mild anal symptoms.
As expected, at follow-up visit anti-Chlamydia IgG
antibodies values were similar to those found at the
moment of LGV diagnosis.
Discussion
In the last decade, a new outbreak of LGV infection with














s was present: HIV, gonorrhoea, non-L CT, HBV, HCV, HPV warts.
e site tested (pharyngeal swab and/or rectal swab and/or urine)
Table 2 Univariate and multivariate logistic regression
analysis for LGV risk factors
Univariate analysis Multivariate analysis
OR (CI 95%) P value OR (CI 95%) P value




HIV 19.12 (4.96-73.61) <0.001 12.64 (3.00-53.25) 0.001
Syphilis 11.10 (3.04-40.54) <0.001 6.72 (1.58-28.45) 0.010
Gonorrhoea 1.37 (0.34-5.54) 0.653
HBV 13.62 (2.62-70.68) 0.002
HCV 7.8 (0.45-133.56) 0.155
HPV warts 3.77 (0.98-14.54) 0.053
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infection show considerable variability, depending on the
characteristics of studied groups, with highest levels on
high-risk selected population [9,10].
In our study, we found 13 cases of rectal LGV in a
high-risk population and prevalence of LGV proctitis
was 12%.
As shown in our investigation, LGV proctitis is usually
symptomatic and it occurs as a moderate or severe ul-
cerative proctitis in more than 90% of cases [11], while
non-LGV CT proctitis remains clinically silent in many
cases [12].
In agreement with international literature [13-15], we
observed that all LGV cases were diagnosed in MSM
and that LGV positive patients were significantly older
than LGV-negative ones (P = 0.0008).
Although patients reported active and passive anal inter-
courses, a LGV urethral infection has not been identified
in our population. This is in concordance with previously
reported studies [2,9] even if recently de Vrieze et al.
found some cases of concurrent urethral LGV in a group
of MSM with anorectal infection [16].
As observed in our cases, LGV proctitis can be easily
misdiagnosed at the first investigations due to the un-
awareness of general practitioners and shame of patients
in seeking care [11]. The most common misdiagnosis
concerns IBD, since both endoscopic appearance of rec-
tal mucosa and histological examination show similar
characteristics [17].
High-risk sexual behaviours, including high number of
sexual partners, unsafe intercourses, fisting and sex toys
sharing are reported by most of LGV infected patients
[18,19]. Common risk behaviours and LGV ulcerative
lesions can both explain the high prevalence of other
STIs found in LGV patients.
Our data highlighted a significant difference between
LGV-positive and LGV-negative subjects regarding coin-
fections due to other STIs (P = 0.0023); in particularamong LGV patients higher rates of HIV (P < 0.001), syph-
ilis (P < 0.001) and HBV (P = 0.001) infections were found.
Logistic regression analysis in our population showed that
HIV and syphilis represent the strongest risk factors for
LGV infection (P < 0.001).
A strong association between anorectal LGV and HIV
seropositivity has been already well documented [18],
with rate of co-infection reaching 60-100% in MSM
population [20].
It has been supposed that HIV-related immunodefi-
ciency could delay LGV clearance [21]. Nevertheless, anti-
biotic treatment for LGV with doxycycline for 21 days
appears to be equally effective both in HIV-negative and
HIV positive patients [14].
As already observed [18], we confirm that LGV clinical
presentation was not influenced by the use of HAART
therapy and LGV outcome did not depend on HIV viral
load or CD4 cell count.
Laboratory investigations have a crucial role in LGV
diagnosis, but the quest for a reliable and simple method
to discriminate between LGV and non-LGV CT infections
is still going on. Both serological and nucleic acid amplifi-
cation techniques (NAATs) indeed present critical issues.
Chlamydia serology can support LGV diagnosis in the
appropriate clinical context, but the diagnostic utility of
serological methods other than complement fixation and
microimmunofluorescence procedures has not been well
established yet [22,23]. In this study, we found a significant
elevation of anti-Chlamydia IgG by an immunoenzimatic
assay in LGV-positive patients, suggesting a potential role
of IgG testing for LGV diagnosis.
On the other hand, NAATs have not been FDA cleared
or CE marked yet on rectal specimens.
For that reason, many laboratories have performed their
own validation studies in order to provide results for
clinical management [22]. Moreover, since commercial
NAATs can not differentiate LGV from non-LGV sero-
vars, further investigations for CT molecular typing are
needed. In the absence of specific LGV diagnostic testing,
patients with a clinical syndrome consistent with LGV,
should be treated with LGV regimen (doxycycline 100 mg
orally twice a day for 21 days) [15,23].
In our experience, even if Versant CT/GC DNA 1.0
Assay has been not licensed for extragenital use, it showed
good performances in CT/GC DNA detection on rectal
and pharyngeal swabs. In addition, RFLP analysis of CT
positive samples seems to be a reliable, inexpensive and
time-saving method for CT genotyping.
It follows that our suggested algorithm (i.e. Versant
CT/GC DNA 1.0 Assay and RLFP analysis of CT positive
samples) could be an excellent choice for laboratory LGV
diagnosis.
Even if our results do not provide sufficient evidence to
recommend routine screening of anorectal swabs in MSM
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guidelines, the indication to perform CT NAAT tests and
genotyping on rectal specimens in presence of ulcerative
proctitis or in sexual contacts of LGV positive people
[9,24].
In particular, our results suggest to test for rectal LGV
all MSM complaining of anorectal symptoms, especially
if other STIs (HIV and/or syphilis) are identified. More-
over, these subjects should be presumptively treated for
LGV infection until CT molecular genotyping is known.
Conclusions
On the strength of our epidemiological and statistical
results, testing for LGV infection should be recommended
to all HIV and/or syphilis-positive MSM complaining of
anorectal symptoms. For this purpose, CT DNA detection
by Versant CT/GC DNA 1.0 Assay, followed by RFLP
analysis for molecular typing demonstrated to be an excel-
lent diagnostic algorithm for LGV identification.
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